Walgreens’ Planned $23.7B Private Equity Deal Could Mark The End of A Century-Long Public Trading Era
The pharmacy giant that once commanded a $100B market value now finds itself swallowing a bitter pill. Walgreens Boots Alliance announced its transition to private ownership through a deal with Sycamore Partners valued at up to $23.7B, marking the end of nearly a century as a publicly traded company. The move comes as the drugstore chain grapples with plummeting market value and widespread store closures.
- The deal values Walgreens at $11.45 per share in cash, representing a ~30% premium over December prices when privatization rumors first surfaced.
- The organization plans to shutter ~1.2K locations by 2027, affecting roughly one in seven stores, as ~25% of its locations currently operate at a loss.
Looking ahead: Walgreens CEO Tim Wentworth emphasized that “meaningful value creation will take time, focus, and change that is better managed as a private company.” However, Sycamore Partners, known for retail turnarounds, faces the challenge of revitalizing a business that’s struggled against CVS in prescription negotiations and weathered competition from Amazon and Target. With the transaction expected to close in Q4 2025, this deal could provide the flexibility needed for Walgreens to reinvent itself away from Wall Street’s scrutiny.
